Reuters logo
BRIEF-Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury
April 12, 2017 / 11:50 AM / 8 months ago

BRIEF-Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury

April 12 (Reuters) - Neuralstem Inc

* Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury

* Neuralstem - New cohort of four patients will be added to ongoing phase 1 human clinical trial for NSI-566 spinal cord-derived neural stem cells

* Neuralstem - Amended protocol was approved by U.S. Food and Drug Administration, institutional review board at study site, University of California San Diego Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below